Regeneron Pharmaceuticals (REGN) Stock Buyback History
TTM buyback yield 4.72% · Shareholder yield (TTM) 4.72%.
TTM buyback yield
4.72%
Shareholder yield (TTM)
4.72%
5Y share count change
-5.6%
TTM buyback spend
$3.79B
SBC coverage (TTM)
3.81x
YoY change in spend
+9.3%
5Y CAGR of spend
-9.5%
Peak year (2020)
$6.53B
Cumulative spend
$24.19B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Regeneron Pharmaceuticals (REGN) repurchased about $3.79B of stock over the trailing twelve months.
- Diluted share count is down 5.6% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 3.81× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at -9.5% per year over the latest 5-year window.
- TTM repurchases used about 100% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $3.97B | $993.70M | $2.98B | 0.11B | -5.6% | 5.00% |
| 2024 | $3.63B | $982.80M | $2.65B | 0.12B | 1.2% | 4.73% |
| 2023 | $2.94B | $885.00M | $2.05B | 0.11B | 0.2% | 3.14% |
| 2022 | $2.53B | $725.00M | $1.80B | 0.11B | 1.2% | 3.28% |
| 2021 | $2.68B | $601.70M | $2.08B | 0.11B | -2.5% | 3.99% |
| 2020 | $6.53B | $432.00M | $6.10B | 0.12B | 0.4% | 12.82% |
| 2019 | $463.90M | $464.30M | −$400.00K | 0.11B | -0.2% | 1.08% |
| 2018 | $191.60M | $427.40M | −$235.80M | 0.11B | -1.0% | 0.45% |
| 2017 | $301.70M | $507.28M | −$205.58M | 0.12B | -0.3% | 0.69% |
| 2016 | $143.20M | $559.88M | −$416.68M | 0.12B | 0.9% | 0.34% |
| 2015 | $160.54M | $459.05M | −$298.51M | 0.12B | 1.6% | 0.26% |
| 2014 | $267.58M | $307.24M | −$39.65M | 0.11B | 2.0% | 0.57% |
| 2013 | $195.09M | $198.40M | −$3.31M | 0.11B | -3.5% | 0.54% |
| 2012 | $163.30M | $94.16M | $69.14M | 0.12B | 27.3% | 0.86% |
| 2011 | $25.08M | $56.09M | −$31.02M | 0.09B | 9.3% | 0.49% |
| 2010 | $3.80M | $39.90M | −$36.10M | 0.08B | 3.9% | 0.13% |
| 2009 | $0.00 | $31.26M | −$31.26M | 0.08B | 1.2% | — |
| 2008 | $0.00 | $32.52M | −$32.52M | 0.08B | 18.8% | — |
| 2007 | $0.00 | $28.07M | −$28.07M | 0.07B | 14.4% | — |
| 2006 | $0.00 | $0.00 | $0.00 | 0.06B | 3.6% | — |
| 2005 | $0.00 | $0.00 | $0.00 | 0.06B | -0.4% | — |
| 2004 | $888.00K | $0.00 | $888.00K | 0.06B | 11.3% | 0.17% |
| 2003 | $0.00 | $0.00 | $0.00 | 0.05B | 14.8% | — |
| 2002 | $0.00 | $0.00 | $0.00 | 0.04B | 4.4% | — |
| 2001 | $0.00 | $0.00 | $0.00 | 0.04B | 19.7% | — |
| 2000 | $0.00 | $0.00 | $0.00 | 0.04B | 11.8% | — |
| 1999 | $0.00 | $0.00 | $0.00 | 0.03B | 1.4% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.03B | 6.9% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.03B | 18.5% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.02B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Regeneron Pharmaceuticals (REGN) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Regeneron Pharmaceuticals (REGN)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Regeneron Pharmaceuticals (REGN)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $3.97B | +9.3% | +$338.30M | ||
| 2024 | $3.63B | +23.7% | +$696.80M | ||
| 2023 | $2.94B | +16.1% | +$407.10M | ||
| 2022 | $2.53B | -5.6% | -$149.60M | ||
| 2021 | $2.68B | -59.0% | -$3.85B | ||
| 2020 | $6.53B | +1307.1% | +$6.06B | ||
| 2019 | $463.90M | +142.1% | +$272.30M | ||
| 2018 | $191.60M | -36.5% | -$110.10M | ||
| 2017 | $301.70M | +110.7% | +$158.50M | ||
| 2016 | $143.20M | -10.8% | -$17.34M | ||
| 2015 | $160.54M | -40.0% | -$107.05M | ||
| 2014 | $267.58M | +37.2% | +$72.50M | ||
| 2013 | $195.09M | +19.5% | +$31.79M | ||
| 2012 | $163.30M | +551.2% | +$138.22M | ||
| 2011 | $25.08M | +560.3% | +$21.28M | ||
| 2010 | $3.80M | — | +$3.80M | ||
| 2009 | $0 | — | $0 | ||
| 2008 | $0 | — | $0 | ||
| 2007 | $0 | — | $0 | ||
| 2006 | $0 | — | $0 | ||
| 2005 | $0 | -100.0% | -$888,000 | ||
| 2004 | $888,000 | — | +$888,000 | ||
| 2003 | $0 | — | $0 | ||
| 2002 | $0 | — | $0 | ||
| 2001 | $0 | — | $0 | ||
| 2000 | $0 | — | $0 | ||
| 1999 | $0 | — | $0 | ||
| 1998 | $0 | — | $0 | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | — | $0 | ||
| 1995 | $0 | — | $0 | ||
| 1994 | $0 | — | $0 | ||
| 1993 | $0 | — | $0 | ||
| 1992 | $0 | — | $0 | ||
| 1991 | $0 | — | — |
In 2025, Regeneron Pharmaceuticals (REGN) buyback spend totalled $3.97B – grew 9.3% year-over-year.
Through 2020–2025 (5 years), Regeneron Pharmaceuticals buyback spend delivered a -9.5% annualised rate; sustaining 3 straight years of year-over-year growth.
Regeneron Pharmaceuticals buyback spend plunged from $6.53B in 2020 to $3.97B in 2025, a 39.2% drawdown.
The dataset's maximum buyback spend sits at $6.53B (2020); the minimum reading of $0 dates to 1991.
Among 8 Healthcare peers, Regeneron Pharmaceuticals (REGN) ranks 5th; the peer median for buyback spend is $2.75B.
Regeneron Pharmaceuticals Buyback Spend 2025: $3.97B
Regeneron Pharmaceuticals buyback spend in 2025 was $3.97B, grew 9.3% from 2024.
Regeneron Pharmaceuticals Buyback Spend 2024: $3.63B
Regeneron Pharmaceuticals buyback spend in 2024 was $3.63B, grew 23.7% from 2023.
Regeneron Pharmaceuticals Buyback Spend 2023: $2.94B
Regeneron Pharmaceuticals buyback spend in 2023 was $2.94B, grew 16.1% from 2022.
Regeneron Pharmaceuticals Buyback Spend 2022: $2.53B
Regeneron Pharmaceuticals buyback spend in 2022 was $2.53B, declined 5.6% below 2021.
Regeneron Pharmaceuticals Buyback Spend 2021: $2.68B
Regeneron Pharmaceuticals buyback spend in 2021 was $2.68B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers by buyback spend
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 3.81×.
Capital allocation mix
How Regeneron Pharmaceuticals splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.78B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Regeneron Pharmaceuticals's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Regeneron Pharmaceuticals buy back its own stock?
Yes, Regeneron Pharmaceuticals (REGN) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does Regeneron Pharmaceuticals spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $3.79B (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is Regeneron Pharmaceuticals's buyback yield?
TTM buyback yield is about 4.72% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is Regeneron Pharmaceuticals's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 4.72% combined (TTM-based where available).
Is Regeneron Pharmaceuticals diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Regeneron Pharmaceuticals's share count changed?
Diluted weighted average shares changed by about -5.6% over roughly five fiscal years (annual income statement data).
What is Regeneron Pharmaceuticals's buyback spend?
Latest reported buyback spend for Regeneron Pharmaceuticals (REGN) is $3.79B (period ending March 31, 2026).
How has Regeneron Pharmaceuticals buyback spend changed year-over-year?
Regeneron Pharmaceuticals (REGN) buyback spend changed +9.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals buyback spend?
Regeneron Pharmaceuticals (REGN) buyback spend compound annual growth rate is -9.5% over the most recent 5 years available.
When did Regeneron Pharmaceuticals buyback spend hit its highest annual value?
Regeneron Pharmaceuticals buyback spend reached its highest annual value of $6.53B in 2020.
What was Regeneron Pharmaceuticals buyback spend in 2024?
Regeneron Pharmaceuticals (REGN) buyback spend in 2024 was $3.63B.
What was Regeneron Pharmaceuticals buyback spend in 2025?
Regeneron Pharmaceuticals (REGN) buyback spend in 2025 was $3.97B.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $473.10 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $140.27 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.92B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Dividend Profile
Yield: 0.56%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
REGN Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
REGN Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.